Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(18):1352-1353; doi:10.1093/jnci/djg071
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sandler, H. M.
Right arrow Articles by DeSilvio, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sandler, H. M.
Right arrow Articles by DeSilvio, M. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

EDITORIAL

Surrogate End Points for Prostate Cancer: What Is Prostate-Specific Antigen Telling Us?

Howard M. Sandler, Michelle L. DeSilvio

Affiliations of authors: H. M. Sandler, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; M. L. DeSilvio, American College of Radiology, Philadelphia, PA.

Correspondence to: Howard M. Sandler, MD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109–0010 (e-mail: hsandler@umich.edu).

The first 10% of the full text of this article appears below.

Prostate cancer is a common malignancy. The observed incidence of prostate cancer has undergone dramatic changes because of the widespread use of prostate-specific antigen (PSA)-based screening. The debate surrounding the use of PSA as a screening method continues, whereas the use of PSA as a tool to detect recurrences of prostate cancer after initial therapy is fully enshrined in the post-therapy routine of patients with prostate cancer. Although defining the precise time of treatment failure after radiation therapy or surgery can be contested (1–3), there is little doubt that a sustained pattern of increasing PSA values after treatment is an indication of the presence of active prostate cancer. Furthermore, just as patients with newly diagnosed prostate cancer often . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
H. Lukka, C. Hayter, J. A. Julian, P. Warde, W. J. Morris, M. Gospodarowicz, M. Levine, J. Sathya, R. Choo, H. Prichard, et al.
Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer
J. Clin. Oncol., September 1, 2005; 23(25): 6132 - 6138.
[Abstract] [Full Text] [PDF]